Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$16.98 USD

16.98
6,213,790

+0.17 (1.01%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $16.98 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Teva Pharmaceutical Industries Ltd. (TEVA) Moves 7.5% Higher: Will This Strength Last?

by Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.

TEVA Beats on Q1 Earnings and Sales, Keeps View, Stock Down

by Zacks Equity Research

TEVA beats on first-quarter earnings and sales. Sales & profits decline year over year. Keeps 2021 view.

Indrajit Bandyopadhyay headshot

3 Generic Drug Stocks to Watch Amid COVID-Related Recovery

by Indrajit Bandyopadhyay

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

Glaxo (GSK) Begins Late-Stage Severe Eosinophilic Asthma Study

by Zacks Equity Research

Glaxo (GSK) is developing an anti-IL-5 monoclonal antibody candidate, GSK3511294 - engineered for high affinity and long-acting suppression of IL-5 function - for treating severe asthma patients.

Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid

by Zacks Equity Research

Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

TEVA Stock Declines Despite Q4 Earnings and Sales Beat

by Zacks Equity Research

TEVA beats on fourth-quarter earnings and sales. It issues its financial guidance for 2021. Stock down.

TEVA Q4 Earnings & Sales Beat Estimates, Stock Rises

by Zacks Equity Research

TEVA beats earnings and sales for fourth-quarter 2020. It issues its financial guidance for 2021. Stock up

Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

TEVA Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On TEVA's fourth-quarter conference call, investors focus is likely to be on updates on the extent to which the resurgence of COVID-19 infection rates impacted sales of its products.

Biohaven (BHVN) Initiates Pivotal Study on OCD Candidate

by Zacks Equity Research

Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.

3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty

by Zacks Equity Research

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is difficult to gauge. However, stable pricing and improvement in demand in some countries in 2021 may bode well for RDY, BHC and VTRS.

Is Teva Pharmaceutical (TEVA) a Good Stock to Pick Now?

by Zacks Equity Research

Is Teva Pharmaceutical (TEVA) a great pick from the value investor's perspective right now? Read on to know more.

Kinjel Shah headshot

6 Low Price-to-Book Value Stocks to Tap Market Boom

by Kinjel Shah

When it comes to valuation metrics, though P/E and P/S are the first choices, the P/B ratio is also emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

TEVA Posts In-Line Q3 Earnings, Lowers Sales View, Stock Down

by Zacks Equity Research

TEVA's earnings match estimates while sales miss the same for third-quarter 2020. It lowers its previously issued sales guidance for 2020. Stock down.

Amarin's (AMRN) Q3 Earnings Lag, Sales In Line, Stock Down

by Zacks Equity Research

Amarin's (AMRN) revenue growth in the third quarter is attributable to continued demand for its cardiovascular drug, Vascepa. Generic competition for Vascepa seems imminent.

TEVA Q3 Earnings In Line, Sales Miss, Stock Down

by Zacks Equity Research

TEVA's earnings match estimates while sales miss the same in third-quarter 2020. It maintains its previously issued guidance for 2020. Stock down.

TEVA Gears Up to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Teva's (TEVA) third-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products.

Kinjel Shah headshot

6 Low Price-to-Book Stocks That May Prove to be Solid Bets

by Kinjel Shah

When it comes to valuation metrics, though P/E and P/S are the first choices, the P/B ratio is also emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

FDA Accepts Biohaven's (BHVN) sNDA for Migraine Drug Nurtec

by Zacks Equity Research

Biohaven (BHVN) is seeking the label expansion of its migraine drug Nurtec ODT as a preventive treatment of migraine.

AbbVie Elezanumab Gets FDA's Fast Track and Orphan Drug Tags

by Zacks Equity Research

AbbVie's (ABBV) elezanumab is presently being evaluated in a phase II study for spinal cord injury.

Satsuma Plunges on Disappointing Data on Migraine Treatment

by Zacks Equity Research

Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.

AstraZeneca's Fasenra Meets Endpoint in Rhinosinusitis Study

by Zacks Equity Research

AstraZeneca (AZN) is developing Fasenra under a clinical program as a potential treatment for chronic rhinosinusitis with nasal polyps.

Amarin Loses Patent Appeal in Vascepa Lawsuit, Stock Dips

by Zacks Equity Research

Amarin (AMRN) receives a setback as the U.S. Court of Appeals upholds a ruling by Nevada district court in favor of the generic companies related to patent litigation against Vascepa.

Teva Stock Down on Charges of Illegal Generic Price Fixing

by Zacks Equity Research

Teva (TEVA) has been indicted on charges of conspiring with other generic drugmakers to raise prices for generic drugs.